<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603497</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK11</org_study_id>
    <nct_id>NCT02603497</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function</brief_title>
  <official_title>Pharmacokinetic (PK) Study of ASP015K -Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Subjects With Normal Renal Function-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the pharmacokinetics of ASP015K in patients with&#xD;
      impaired renal function and subjects with normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Actual">December 19, 2016</completion_date>
  <primary_completion_date type="Actual">December 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP015K: AUCinf</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP015K: Cmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: AUCinf</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: Cmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Hematology, blood biochemistry and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: AUClast</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: t1/2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: tmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: CL/F</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: Vz/F</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: AUClast</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: t1/2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: tmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Patients With Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Control (Subjects with normal renal function)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>Control (Subjects with normal renal function)</arm_group_label>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subject&#xD;
&#xD;
          -  Body weight): ≥40.0 kg and &lt;90.0 kg&#xD;
&#xD;
          -  Body mass index BMI: ≥17.6 and &lt;30.0&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be post-menopausal or surgically sterile.&#xD;
&#xD;
               -  Agree not to try to become pregnant starting at the time of informed consent&#xD;
                  throughout the study period and for 60 days after the final study drug&#xD;
                  administration if she is of childbearing potential.&#xD;
&#xD;
          -  Female subjects who agree not to breastfeed starting at informed consent and&#xD;
             throughout the study period and for 60 days after the final study drug administration&#xD;
&#xD;
          -  Agree not to donate ova for female / sperm for male starting at informed consent and&#xD;
             throughout the study period and for 60/90 days after the final study drug&#xD;
             administration&#xD;
&#xD;
          -  Agree to use highly effective contraception&#xD;
&#xD;
        Patients with impaired renal function&#xD;
&#xD;
          -  Patients with eGFR by GFR predictive equation for Japanese within the following ranges&#xD;
             at screening and who is not undergoing dialysis.&#xD;
&#xD;
               -  Patients with mild impaired renal function (eGFR; ≥60 mL/min/1.73 m2 and &lt;90&#xD;
                  mL/min/1.73 m2)&#xD;
&#xD;
               -  Patients with moderate impaired renal function (eGFR; ≥30 mL/min/1.73 m2 and &lt;60&#xD;
                  mL/min/1.73 m2)&#xD;
&#xD;
               -  Patients with severe impaired renal function (eGFR; ≥15 mL/min/1.73 m2 and &lt;30&#xD;
                  mL/min/1.73 m2)&#xD;
&#xD;
          -  Patients whose treatment regimen (including diet) for renal impairment or&#xD;
             complications remain unchanged within 14 days prior to hospital admission day (Day&#xD;
             -1), or patients who receive treatments (including diet) that need not to be changed&#xD;
             during the period from 14 days before hospital admission day (Day -1) to follow-up&#xD;
             examination in the opinion of the investigator or sub-investigator.&#xD;
&#xD;
        Subjects with normal renal function&#xD;
&#xD;
          -  Subjects with eGFR by GFR predictive equation for Japanese ≥ 90 mL/min/1.73 m2 at&#xD;
             screening&#xD;
&#xD;
          -  Subjects who is healthy, as judged by the investigator or sub-investigator based on&#xD;
             physical examinations (subjective symptoms and objective findings) and all tests&#xD;
             obtained at screening and during the period from hospital admission to immediately&#xD;
             before study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Received or is scheduled to receive any study drugs in other clinical trials or&#xD;
             post-marketing studies within 120 days before screening or during the period from&#xD;
             screening to the hospital admission day (Day -1)&#xD;
&#xD;
          -  Deviate from the following provided range of blood pressure, pulse rate, body&#xD;
             temperature and standard 12-lead ECG at screening or the hospital admission day (Day&#xD;
             -1)&#xD;
&#xD;
          -  Subjects who meet any of the criteria for laboratory tests at screening or the&#xD;
             hospital admission day (Day -1). Normal ranges of each test specified at the study&#xD;
             site or the test/assay organization will be used as the normal ranges in this study.&#xD;
&#xD;
          -  Complication or history of drug allergies&#xD;
&#xD;
          -  Developed upper gastrointestinal symptoms within 7 days before the hospital admission&#xD;
             day (Day -1)&#xD;
&#xD;
          -  Complication or history of hepatic disease&#xD;
&#xD;
          -  Complication of long QT syndrome, congenital short QT syndrome&#xD;
&#xD;
          -  A history of gastrointestinal resection&#xD;
&#xD;
          -  Subjects with a complication or history of endocrine disease&#xD;
&#xD;
          -  Subjects with a complication or history of malignant tumor&#xD;
&#xD;
          -  Subjects with a complication or history of lymphatic disease&#xD;
&#xD;
          -  Applies to any of following concerns of tuberculosis&#xD;
&#xD;
               -  A history of active tuberculosis&#xD;
&#xD;
               -  Abnormalities detected on a chest X-ray test (at screening)&#xD;
&#xD;
               -  Contact with infectious tuberculous patients&#xD;
&#xD;
          -  Applies to any of following concerns, with regard to infection except for tuberculosis&#xD;
&#xD;
               -  A complication or history of severe herpes zoster or herpes zoster disseminated&#xD;
&#xD;
               -  At least twice of relapse of localized herpes zoster&#xD;
&#xD;
               -  Inpatient hospital care for severe infectious diseases within 90 days before the&#xD;
                  hospital admission day (Day -1)&#xD;
&#xD;
               -  Treatment with intravenous antibiotics within 90 days before the hospital&#xD;
                  admission day (Day -1) (prophylactic antibiotics are not applicable).&#xD;
&#xD;
               -  Other than above, a subject with a high risk of developing infectious disease&#xD;
                  (e.g. subjects with urethral catheterisation) in judgment of the investigator or&#xD;
                  sub-investigator.&#xD;
&#xD;
          -  Vaccination of live vaccines or live attenuated vaccines within 56 days before the&#xD;
             hospital admission day (Day -1) (Inactivated vaccines such as influenza vaccine and&#xD;
             pneumococcal vaccine are not applicable.)&#xD;
&#xD;
          -  A history of clinically serious allergies&#xD;
&#xD;
          -  Previously received administration of ASP015K&#xD;
&#xD;
          -  Excessive alcohol drinking or smoking&#xD;
&#xD;
        Patients with impaired renal function&#xD;
&#xD;
          -  Patients who received or are scheduled to receive any new drugs within 14 days before&#xD;
             the hospital admission day (Day -1)&#xD;
&#xD;
          -  Patients who receive dialysis, or received renal transplantation&#xD;
&#xD;
          -  Patients who developed acute changes in renal function and in all laboratory test&#xD;
             results within 28 days before screening and patients with impaired renal function who&#xD;
             may need new concomitant therapies during the study period.&#xD;
&#xD;
          -  Patients with a complication of severe heart disease, NYHA class III or IV cardiac&#xD;
             failure.&#xD;
&#xD;
          -  Complication of alimentary disease, cerebrovascular disorder, respiratory disease&#xD;
&#xD;
          -  Patients with tubular dysfunction, obvious urination impaired&#xD;
&#xD;
        Subjects with normal renal function&#xD;
&#xD;
          -  Subjects who received or is scheduled to receive medications (including&#xD;
             over-the-counter [OTC] drugs) within seven days before the hospital admission day (Day&#xD;
             -1).&#xD;
&#xD;
          -  Subjects with a complication or history of heart disease, respiratory disease,&#xD;
             alimentary disease, renal disease, endocrine disease, urological disease,&#xD;
             cerebrovascular disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>impaired renal function</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

